Eevia Health: Record-Level Margins Generate Substantial Bottom-Line Profits - Analyst Group

Eevia Health Plc (publ) (”Eevia Health”, “Eevia” or “the Company”) is at a stage where the Company is scaling up the production capacity, focusing on higher margin extracts, and developing new proprietary ingredients targeting eye disorders, which constitute strong value drivers ahead. Having a broad product portfolio with a market demand, Eevia is estimated to enter a rapid growth phase where an EBIT of EUR 4.8m is forecasted. Based on an applied EV/EBIT multiple of 4.5x on the estimated EBIT of EUR 4.8m in year 2026, and a discount rate of 12%, this yields an implied value per share of SEK 4.9 (3.8) in a Base scenario. Given that Eevia takes steps in the right direction and is able to capitalise on the structural market trends, Analyst Group see a potential for the Company to reduce the valuation discount going forward.

Länk till analysen i sin helhet: https://mfn.se/a/analyst-group/eevia-health-record-level-margins-generate-substantial-bottom-line-profits